Mirabegron Clonmel (Mirabegron)

Mirabegron selectively activates β3‑adrenergic receptors located in the bladder’s smooth muscle. This activation triggers a cascade that relaxes the detrusor muscle during the storage phase, allowing the bladder to hold more urine and decreasing the urge to void.

The dose of Mirabegron is individualized by the prescribing clinician. Typically, treatment begins with a low daily dose, which may be adjusted based on therapeutic response and tolerability, but the exact regimen should always follow the prescriber’s instructions.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Mirabegron Clonmel product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Antimuscarinics such as oxybutynin reduce bladder contractions by blocking muscarinic receptors, often causing dry mouth and constipation. Mirabegron, a β3‑adrenergic agonist, works via a different pathway and generally has a lower incidence of anticholinergic side effects, making it a useful alternative for patients who cannot tolerate antimuscarinics.

Mirabegron tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources, and keep the container tightly closed when not in use.

Mirabegron is taken orally as a tablet, usually once daily. The tablet should be swallowed whole with a glass of water and can be taken with or without food, as directed by the prescribing clinician.

Serious adverse events include significant hypertension, tachycardia, and rare cases of angioedema or severe urinary retention that may require catheterisation. Patients should be monitored for rapid increases in blood pressure or heart rate, and any signs of swelling in the face, lips or throat should prompt immediate medical attention.

Mirabegron is contraindicated in individuals with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to the drug. Patients with these conditions should avoid the medication and discuss alternative treatment options with their healthcare provider.